Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.

MLA

Lo Prinzi, Federica, et al. “Efficacy of Cisplatin-Gemcitabine-Durvalumab in Patients with Advanced Biliary Tract Cancer Experiencing Early vs Late Disease Relapse after Surgery: A Large Real-Life Worldwide Population.” The Oncologist, Oct. 2024. EBSCOhost, https://doi.org/10.1093/oncolo/oyae256.

APA

Lo Prinzi, F., Salani, F., Rimini, M., Rizzato, M. D., Antonuzzo, L., Camera, S., Satake, T., Vandeputte, H., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., Giordano, G., Pircher, C., Chon, H. J., … Casadei-Gardini, A. (2024). Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population. The Oncologist. https://doi.org/10.1093/oncolo/oyae256

Chicago

Lo Prinzi, Federica, Francesca Salani, Margherita Rimini, Mario Domenico Rizzato, Lorenzo Antonuzzo, Silvia Camera, Tomoyuki Satake, et al. 2024. “Efficacy of Cisplatin-Gemcitabine-Durvalumab in Patients with Advanced Biliary Tract Cancer Experiencing Early vs Late Disease Relapse after Surgery: A Large Real-Life Worldwide Population.” The Oncologist, October. doi:10.1093/oncolo/oyae256.